Newly Public Rosetta Genomics Says Q4 R&D Rises 30 Percent; No Revenue Yet | GenomeWeb
NEW YORK (GenomeWeb News) — Rosetta Genomics today released its first earnings statement as a new public company, saying it generated no revenues in the fourth quarter, R&D spending increased 30 percentl, and net losses increased 16 percent.
 
R&D spending for the three months ended Dec. 31, 2006, increased to $1.3 million from $1 million in the year-ago period.
 
The company said net loss increased to $2.1 million from $1.8 million in the fourth quarter of 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.